



26 Aug 2009

## **EU Multi-centre trial begins**

Zilico confirmed that it has started a European multi-centre trial in April 2009. This trial is designed to demonstrate the performance of its portable diagnostic device within a cervical cancer screening programme. The device is positioned as an adjunct to colposcopy to help accurately identify sites for biopsy. The trial will be carried out across four centres and will recruit around 600 women.

Zilico is a medical diagnostics company which is developing a medical device to provide real-time diagnosis for cervical cancer. The first application is aimed at the colposcopy, or referral market, and its second application is aimed at the point-of-care (POC) market.

Sameer Kothari, CEO of Zilico, commented: "Our most recent published data has given us the confidence that the device is accurately measuring the true state of the underlying tissue of the cervix. This trial will further underwrite this."

The latest data was recently presented at the British Society of Colposcopy and Cervical Pathology (BSCCP) meeting in Dublin, Ireland by John Tidy, clinical founder of Zilico and has been accepted for publication in a peer-reviewed clinical journal.

### ***For more information please contact:***

Sameer Kothari, CEO, Zilico Ltd, tel: 0114 222 4580; email: [sameer.kothari@zilico.co.uk](mailto:sameer.kothari@zilico.co.uk)

### **Notes for editors:**

Zilico Ltd is a company developing the next generation of cancer diagnostics with a product line which will provide real-time diagnostics for cervical cancer. Two products are under development: the first for the referral market and the second for the screening market. Clinical data on 500 women has demonstrated superior performance over existing diagnostic procedures.

Zilico has developed Electrical Impedance Spectroscopy EIS, an objective scientifically-proven method to differentiate between normal, pre cancerous and cancerous cells. This provides a real-time diagnosis that removes subjectivity at both screening and referral, and potentially avoids the need for a biopsy. Zilico's patented technology, which has been discussed in learned peer-reviewed journals, exploits the different electrical resistivity of normal, pre-cancerous and cancerous cells.

Since incorporation in 2006, Zilico (previously known as Aperio Diagnostic Ltd) has focused on developing a research-based instrument into a device appropriate for commercial manufacture and routine use by medical practitioners. Both Zilico products consist of a handheld device and a base unit together with a single-use disposable sleeve for each test.